Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of pimecrolimus cream 1% in its registered indication
(treatment of patients > 3 months of age with mild to moderate atopic dermatitis)
This study is not enrolling patients in the United States.